RNA interference: cellular gene-silencing by small RNAs

Core mechanism and molecular components

Two main classes of small RNAs mediate RNAi activity: small interfering RNA (siRNA) and microRNA (miRNA). Both arise from longer double-stranded RNA (dsRNA) or hairpin precursors and are processed into short duplexes by the RNase III enzyme Dicer. One strand of the duplex is incorporated into an effector complex called RISC (RNA-induced silencing complex), whose central protein is a member of the Argonaute family. Guided by base pairing between the small RNA and a target mRNA, RISC can either cleave the mRNA, inhibit its translation, or promote its decay.

• Dicer: processes long dsRNA into ~20–25 nt duplexes.
• Argonaute/RISC: binds the guide strand and executes silencing.
• siRNA vs miRNA: siRNAs usually pair perfectly and direct cleavage; miRNAs often pair imperfectly to repress translation and destabilize transcripts.

Biological roles and significance

RNAi contributes to multiple cellular functions. It acts as a defence mechanism against invading viruses and suppresses transposable elements to preserve genome integrity. In multicellular organisms, small RNAs guide spatial and temporal control of gene activity during development, cell differentiation, and maintenance of cellular identity. More broadly, RNAi influences global patterns of gene expression across many tissues.

History and discovery

The phenomenon that double-stranded RNA could silence genes was first characterized in the nematode nematode Caenorhabditis elegans in experiments published in 1998. This work, which elucidated a new layer of post-transcriptional control, led to the award of the Nobel Prize in Physiology or Medicine in 2006 to Andrew Fire and Craig Mello.

Research tools and practical applications

Researchers exploit RNAi to reduce expression of individual genes and study their function. Synthetic dsRNA or chemically designed siRNAs can be introduced into cultured cells or whole organisms to produce specific knockdowns, enabling systematic screens of genes involved in processes such as cell division. In agriculture and biotechnology, RNAi is used to alter traits, protect crops from pests, or control viral infection. In clinical contexts, RNAi-based approaches are being developed and some have progressed to approved therapies or clinical trials, illustrating promise for medicine.

Limitations, distinctions and notable points

Despite its power, practical use of RNAi faces challenges: effective delivery into target cells, potential off-target effects where similar sequences are unintentionally suppressed, and innate immune activation in some hosts. The detailed mechanisms and outcomes differ between species and cell types; for example, plants and invertebrates often mount robust antiviral RNAi responses, whereas mammalian responses can be more complex and involve additional layers of regulation. Careful experimental design and validation are essential when using RNAi as a research or therapeutic tool.

For deeper protocols, reviews and databases, consult specialist resources and primary literature via institutional portals or authoritative reviews (gene regulation, eukaryotes). Historical and foundational accounts are available describing the early experiments in C. elegans and the original reports by Fire and Mello.

Further reading and resources: introductory primers, methodological guides, and clinical summaries are widely available from scientific organizations and journals (nematode research groups, siRNA design portals, and translational biotechnology reviews).